Assembly Biosciences, Inc. Earnings Per Share (Basic)
Assembly Biosciences, Inc. (ASMB) reported Earnings Per Share (Basic) of -$0.20 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Assembly Biosciences, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.20.
- Assembly Biosciences, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.54.
- Assembly Biosciences, Inc. earnings per share, basic for the quarter ending 2025-12-31 was $1.30.
- Assembly Biosciences, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.72.
- Assembly Biosciences, Inc. earnings per share, basic for fiscal 2025 was -$0.55.
- Assembly Biosciences, Inc. earnings per share, basic for fiscal 2024 was -$6.69.
- Assembly Biosciences, Inc. earnings per share, basic for fiscal 2023 was -$13.38.
- Assembly Biosciences, Inc. earnings per share, basic for fiscal 2022 was -$23.08.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.20 10-Q · filed 2026-08-13 | -$0.72 10-Q · filed 2026-08-13 | $0.52 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.00 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.54 10-Q · filed 2026-05-07 | $0.77 derived: net income ÷ weighted average shares · filed 2026-05-07 | $0.25 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-12-31 | $1.30 derived: net income ÷ weighted average shares · filed 2026-04-22 | $0.87 derived: net income ÷ weighted average shares · filed 2026-04-22 | $0.22 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.55 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | -$0.72 10-Q · filed 2025-11-10 | -$1.91 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.03 10-Q · filed 2025-11-10 | -$4.48 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$1.33 10-Q · filed 2026-08-13 | -$2.51 10-Q · filed 2026-08-13 | -$4.06 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$5.56 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-03-31 | -$1.17 10-Q · filed 2026-05-07 | -$2.73 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$4.23 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$6.13 derived: net income ÷ weighted average shares · filed 2026-05-07 | ||||
| 2024-12-31 | -$1.58 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$3.10 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$5.04 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$6.69 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | -$1.51 10-Q · filed 2025-11-10 | -$3.46 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$5.12 10-Q · filed 2025-11-10 | -$7.16 derived: net income ÷ weighted average shares · filed 2026-04-22 | ||||
| 2024-06-30 | -$1.98 10-Q · filed 2025-08-06 | -$3.64 10-Q · filed 2025-08-06 | -$5.69 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$8.76 derived: net income ÷ weighted average shares · filed 2026-04-22 | ||||
| 2024-03-31 | -$1.66 10-Q · filed 2025-05-08 | -$3.71 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$6.81 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$10.51 derived: net income ÷ weighted average shares · filed 2026-04-22 | ||||
| 2023-12-31 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$5.23 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$9.02 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$13.38 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | -$3.29 10-Q · filed 2024-11-07 | -$0.27 10-Q · filed 2023-11-08 | -$7.17 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$11.61 10-Q · filed 2024-11-07 | -$0.97 10-Q · filed 2023-11-08 | $2.51 derived: net income ÷ weighted average shares · filed 2024-11-07 | ||
| 2023-06-30 | -$3.88 10-Q · filed 2024-08-08 | -$0.32 10-Q · filed 2023-08-09 | -$8.33 10-Q · filed 2024-08-08 | -$0.69 10-Q · filed 2023-08-09 | $1.45 derived: net income ÷ weighted average shares · filed 2024-08-08 | $4.54 derived: net income ÷ weighted average shares · filed 2024-08-08 | ||
| 2023-03-31 | -$4.46 10-Q · filed 2024-05-08 | -$0.37 10-Q · filed 2023-05-04 | $0.66 derived: net income ÷ weighted average shares · filed 2024-05-08 | $2.54 derived: net income ÷ weighted average shares · filed 2024-05-08 | $12.83 derived: net income ÷ weighted average shares · filed 2024-05-08 | |||
| 2022-12-31 | $0.17 derived: net income ÷ weighted average shares · filed 2024-03-28 | $1.13 derived: net income ÷ weighted average shares · filed 2024-03-28 | $6.56 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$23.08 10-K · filed 2024-03-28 | -$1.92 10-K · filed 2023-03-22 | |||
| 2022-09-30 | -$0.48 10-Q · filed 2023-11-08 | -$0.98 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$1.46 10-Q · filed 2023-11-08 | -$2.76 derived: net income ÷ weighted average shares · filed 2023-11-08 | ||||
| 2022-06-30 | -$0.51 10-Q · filed 2023-08-09 | -$0.99 10-Q · filed 2023-08-09 | -$2.29 derived: net income ÷ weighted average shares · filed 2023-08-09 | -$2.71 derived: net income ÷ weighted average shares · filed 2023-08-09 | ||||
| 2022-03-31 | -$0.48 10-Q · filed 2023-05-04 | -$1.79 derived: net income ÷ weighted average shares · filed 2023-05-04 | -$2.21 derived: net income ÷ weighted average shares · filed 2023-05-04 | -$2.77 derived: net income ÷ weighted average shares · filed 2023-05-04 | ||||
| 2021-12-31 | -$1.34 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$1.75 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$2.31 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$3.00 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | -$0.41 10-Q · filed 2022-11-08 | -$0.96 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.63 10-Q · filed 2022-11-08 | |||||
| 2021-06-30 | -$0.55 10-Q · filed 2022-08-09 | -$1.23 10-Q · filed 2022-08-09 | ||||||
| 2020-12-31 | -$1.11 10-K · filed 2021-02-25 | |||||||
| 2020-09-30 | -$0.09 10-K · filed 2021-02-25 | |||||||
| 2020-06-30 | $0.21 10-Q · filed 2021-08-05 | -$0.55 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | -$0.76 10-K · filed 2021-02-25 | |||||||
| 2019-09-30 | -$0.96 10-Q · filed 2019-11-07 | -$2.74 10-Q · filed 2019-11-07 | ||||||
| 2019-06-30 | -$0.72 10-Q · filed 2020-08-05 | -$1.77 10-Q · filed 2020-08-05 | ||||||
| 2019-03-31 | -$1.05 10-Q · filed 2020-05-08 | |||||||
| 2018-09-30 | -$0.87 10-Q · filed 2019-11-07 | -$2.95 10-Q · filed 2019-11-07 | ||||||
| 2018-06-30 | -$1.30 10-Q · filed 2019-08-05 | -$2.11 10-Q · filed 2019-08-05 | ||||||
| 2018-03-31 | -$0.80 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |